Todos Medical Launches Phase 2 Clinical Trial of Its Antiviral 3CL Protease Inhibitor NLC-V-01 (Tollovir) in Hospitalized COVID-19 Patients

Stock Information for Todos Medical Ltd

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Todos Medical Ltd

Todos Medical Announces Insolvency Proceedings in Israel
Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid(TM) and Tollovir(TM) Ingredients
Todos Medical Supports Long COVID Awareness Day
Todos Medical Provides Corporate Update
Todos Medical to Present at the RHK 2022 Disruptive Growth Conference
Todos Medical's 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022
Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network
Todos Medical Announces Third Quarter 2022 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.